DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

MGH team develops a potential alternative to gadolinium-based contrast agents Made of the vital element manganese

Global PET/CT scanner market projected to reach $2.1 billion by 2023 Growth spurred in part by increased Medicare coverage

Can theranostics be the key to completely curing colorectal cancer? Preclinical trials yield promising results

Cerveau Technologies to collaborate in development of PET imaging agents for Alzheimer’s disease

MJFF and Tau Consortium partner to accelerate the development of new PET tracers May detect early stage neurodegenerative disease

Cerveau inks deal with AbbVie for investigational tau imaging PET agent Stage III clinical trial to begin in next few months

New molecular imaging technology for prostate cancer may improve surgical outcomes Lightpoint Medical forges new partnerships

New imaging system may accelerate drug development for Alzheimer's cryo-MOST provides more detail than MR and PET

Phase I trial demonstrates safe use of radiotracer produced in minutes Manufactured using a Ga-68 generator and a cold kit vial

Bracco Imaging acquires SurgVision Enables development of a real-time fluorescence image-guided surgery platform

A brain showing decreases of
serotonin transporters (blue)
in the MCI group compared
to the healthy control group

Courtesy of Gwenn Smith lab

Researchers leverage PET and MR to uncover serotonin's role in Alzheimer's

by Lauren Dubinsky , Senior Reporter
Serotonin may have more to do with Alzheimer’s disease than previously thought.

A team at Johns Hopkins Medicine used PET and MR imaging to measure patients’ brain structures and levels of serotonin and found that lower levels may contribute to the onset of the disease. A report on this research was published in the September issue of Neurobiology of Disease.

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras



“The study shows that the serotonin system is affected in the early stages before memory problems are severe enough to meet criteria for dementia,” Dr. Gwenn Smith, professor and director of geriatric psychiatry and neuropsychiatry at the university, told HCB News. “We hope the study will stimulate development of medications targeting the serotonin system for use in individuals at risk for dementia.”

Previous studies have shown that Alzheimer’s and severe cognitive decline are associated with a significant loss of serotonin neurons, but it was unclear whether it was a cause or consequence of the disease.

Smith and her colleagues had 28 participants with mild cognitive impairment (MCI) and 28 healthy, matched controls undergo MR and PET exams. During the PET exams, a chemical labeled with a radioactive carbon was administered that’s similar in structure to an antidepressant, but not at a dose that would produce a pharmacological effect.

“Brain regions such as the hippocampus that are affected early in AD can be imaged in more detail with MR compared to CAT scans,” said Smith “Neurotransmitters in the brain such as serotonin and dopamine can only be imaged with selective radiotracers that are available for PET and SPECT imaging.”

They found that those with MCI had up to 38 percent less of the serotonin transporter SERT in their brains, compared to the health control group. None of the participants with MCI had higher levels of SERT than their healthy counterparts.

The participants also underwent learning and memory tests including the California Verbal Learning Test, which is scored on a scale of 0 to 80 with a higher number reflecting better memory. The healthy participants scored an average of 55.8 and those with MCI scored an average of 40.5.

For the Brief Visuospatial Memory Test, the participants were shown a series of shapes to remember and draw later. On a scale of 0 to 36, with 36 being the top score, the healthy group scored an average of 20 and those with MCI scored an average of 12.6.

The research team compared the results of the brain imaging tests with the two memory tests and found that lower serotonin transporters correlated with lower scores. For instance, those with MCI had 37 percent lower verbal memory scores and 18 percent lower levels of SERT in the hippocampus than healthy controls.

The team is currently investigating whether PET imaging of serotonin could be a marker to detect the progression of the disease, either alone or in conjunction with scans that detect amyloid.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED